Filter by: Subject

Filter by: Subject

Results Per Page:

Heart failure (HF) (1)
Heart rate variability (HRV) (1)
Heavy metals (1)
Helicobacter pylori infections -- South Africa (1)
Hemoglobinuria (1)
Hepatic venous collateral continuation (1)
Hepatitis C virus (HCV) (1)
Hepatomegaly (1)
Hepatopulmonary syndrome (1)
Hepatosplenomegaly (1)
HEQC’s institutional audits (1)
Herd protection (1)
Heteroplasmy (1)
High flow nasal cannula (HFNC) (1)
High flow nasal oxygen (1)
High risk population (1)
High-risk pregnancy (1)
Higher Education Quality Committee (HEQC) (1)
Highly active anti-retroviral treatment (HAART) (1)
Histidine (1)
Histone acetyltransferase (1)
Histoplasmosis (1)
HIV (1)
HIV care coverage (1)
HIV counseling and testing (HCT) (1)
HIV infection (1)
HIV infections (1)
HIV infections -- Africa, Sub-Saharan (1)
HIV prevention intervention (1)
HIV replication (1)
HIV status (1)
HIV-1 (1)
HIV-1 infection (1)
HIV-associated thrombosis (1)
HIV-infected patients (1)
HIV/AIDS (1)
Hollow fiber model (1)
Homocysteine (1)
Horizontal transmission (1)
Hospital environment (1)
Hospital utilization -- South Africa -- Gauteng (1)
Hospitalised cases (1)
Hospitals (1)
Hospitals -- Rates (1)
Host defences (1)
Host innate immune system (1)
Human association (1)
Human beings (1)
Human host (1)
Human papillomavirus (HPV) (1)
Human populations (1)
Human reproduction -- Endocrine aspects (1)
Human skin volatiles (1)
Humans (1)
Humoral response kinetics (1)
Hypercalcaemia (1)
Hypercholesterolaemia (1)
Hypercholesterolemia (1)
Hyperglycemia -- Treatment -- South Africa (1)
Hyperhomocysteinemia (1)
Hyperlipidemia (1)
Hypertension -- Diagnosis (1)
Hypertension -- Treatment (1)
Hypertension in old age -- Treatment (1)
Hyperthyroidism (1)
Hypertrophic cardiomyopathy (1)
Hypocalcaemia (1)
Hypogonadism (1)
Hypothetical scenarios (1)
Hypoxaemia (1)
Hypoxia (1)
IA-2 (1)
Idiopathic inflammatory myositis (IIM) (1)
IgG2 concentrations (1)
IL8 (1)
Imidazole anti-mycotics (1)
Immune (1)
Immune checkpoint inhibitor (ICI) (1)
Immune checkpoint inhibitor pneumonitis (ICI-Pneumonitis) (1)
Immune checkpoint inhibitors (ICIs) (1)
Immune dysregulation (1)
Immune regulation (1)
Immune system (1)
Immune-related adverse events (irAEs) (1)
Immunocompromised individuals (1)
Immunogenicity (1)
Immunoglobulin A (1)
Immunoglobulin g (IGG) (1)
Immunoglobulin G antibody (1)
Immunoglobulin M (IgM) (1)
Immunosuppressed patients (1)
Immunosuppressive agents -- South Africa (1)
Immunotherapy (1)
Impact of treatment (1)
Implementation strategy (1)
In vitro (1)
Inadequate response (1)
Incidence (1)
Inco-ordination (1)
Incretins (1)